File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1111/bcpt.13332
- Scopus: eid_2-s2.0-85074564921
- PMID: 31597008
- WOS: WOS:000492767400001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Lipocalin‐2—The myth of its expression and function
Title | Lipocalin‐2—The myth of its expression and function |
---|---|
Authors | |
Keywords | biomarker heart failure kidney injury lipocalin‐2 metabolic diseasec |
Issue Date | 2020 |
Publisher | Wiley-Blackwell Publishing Ltd. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1742-7843/ |
Citation | Basic & Clinical Pharmacology & Toxicology, 2020, v. 127 n. 2, p. 142-151 How to Cite? |
Abstract | Lipocalin‐2 is a functional biomarker for acute and chronic kidney diseases, heart failure and obesity‐related medical complications. It is rapidly induced in epithelial cells under stress conditions, but constitutively produced from pre‐adipocytes and mature adipocytes. Measuring the lipocalin‐2 levels represents an effective approach for risk prediction, patient stratification and disease management. Nevertheless, due to ligand‐binding, post‐translational modification and protein‐protein interaction, lipocalin‐2 exists as multiple variants that elicit different pathophysiological functions. To characterize the specific structure‐functional relationships of lipocalin‐2 variants is critical for the development of biomarker assays with sufficient precision and reliability. Moreover, identifying the pathological forms of lipocalin‐2 will provide new therapeutic targets and treatment approaches for obesity‐related complications. |
Persistent Identifier | http://hdl.handle.net/10722/293760 |
ISSN | 2021 Impact Factor: 3.688 2020 SCImago Journal Rankings: 0.805 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Li, D | - |
dc.contributor.author | Sun, WY | - |
dc.contributor.author | Fu, B | - |
dc.contributor.author | Xu, A | - |
dc.contributor.author | Wang, Y | - |
dc.date.accessioned | 2020-11-23T08:21:25Z | - |
dc.date.available | 2020-11-23T08:21:25Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | Basic & Clinical Pharmacology & Toxicology, 2020, v. 127 n. 2, p. 142-151 | - |
dc.identifier.issn | 1742-7835 | - |
dc.identifier.uri | http://hdl.handle.net/10722/293760 | - |
dc.description.abstract | Lipocalin‐2 is a functional biomarker for acute and chronic kidney diseases, heart failure and obesity‐related medical complications. It is rapidly induced in epithelial cells under stress conditions, but constitutively produced from pre‐adipocytes and mature adipocytes. Measuring the lipocalin‐2 levels represents an effective approach for risk prediction, patient stratification and disease management. Nevertheless, due to ligand‐binding, post‐translational modification and protein‐protein interaction, lipocalin‐2 exists as multiple variants that elicit different pathophysiological functions. To characterize the specific structure‐functional relationships of lipocalin‐2 variants is critical for the development of biomarker assays with sufficient precision and reliability. Moreover, identifying the pathological forms of lipocalin‐2 will provide new therapeutic targets and treatment approaches for obesity‐related complications. | - |
dc.language | eng | - |
dc.publisher | Wiley-Blackwell Publishing Ltd. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1742-7843/ | - |
dc.relation.ispartof | Basic & Clinical Pharmacology & Toxicology | - |
dc.rights | Preprint This is the pre-peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. Postprint This is the peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. | - |
dc.subject | biomarker | - |
dc.subject | heart failure | - |
dc.subject | kidney injury | - |
dc.subject | lipocalin‐2 | - |
dc.subject | metabolic diseasec | - |
dc.title | Lipocalin‐2—The myth of its expression and function | - |
dc.type | Article | - |
dc.identifier.email | Li, D: dahuihk@HKUCC-COM.hku.hk | - |
dc.identifier.email | Xu, A: amxu@hkucc.hku.hk | - |
dc.identifier.email | Wang, Y: yuwanghk@hku.hk | - |
dc.identifier.authority | Xu, A=rp00485 | - |
dc.identifier.authority | Wang, Y=rp00239 | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1111/bcpt.13332 | - |
dc.identifier.pmid | 31597008 | - |
dc.identifier.scopus | eid_2-s2.0-85074564921 | - |
dc.identifier.hkuros | 320055 | - |
dc.identifier.volume | 127 | - |
dc.identifier.issue | 2 | - |
dc.identifier.spage | 142 | - |
dc.identifier.epage | 151 | - |
dc.identifier.isi | WOS:000492767400001 | - |
dc.publisher.place | United Kingdom | - |
dc.identifier.issnl | 1742-7835 | - |